Thornton J.W. Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proc Natl Acad Sci U S A 2001;98(10):5671–6.
DOI: 10.1073/pnas.091553298
McLachlan J.A. Environmental signalling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev 2001;22(3):319–41.
DOI: 10.1210/edrv.22.3.0432
Oettel M., Mukhopadhyay A.K. Progesterone: the forgotten hormone in men? Aging Male 2004;7(3):236–57.
DOI: 10.1080/13685530400004199
Foresta C., Rossato M., Mioni R., Zorzi M. Progesterone induces capacitation in human spermatozoa. Andrologia 1992;24(1):33–5.
DOI: 10.1111/j.1439-0272.1992.tb02605.x
Pietrobon E.O., Los Monclus M., Alberdi A.J., Fornés M.W. Progesterone receptor availability in mouse spermatozoa during epididymal transit and capacitation: ligand blot detection of progesterone-binding protein. J Androl 2003;24(4):612–20.
DOI: 10.1002/j.1939-4640.2003.tb02713.x
Baranizadeh K., Mahboobian M.M., Amiri I. et al. Effects of progesterone nanoparticles on the sperm capacitation and acrosome reaction in asthenozoospermia men. Andrologia 2022;54(1):e14258.
DOI: 10.1111/and.14258
Rasmusson A.M., Pineles S.L., Brown K.D., Pinna G. A role for deficits in GABAergic neurosteroids and their metabolites with NMDA receptor antagonist activity in the pathophysiology of posttraumatic stress disorder. J Neuroendocrinol 2022;34(2):e13062.
DOI: 10.1111/jne.13062
Baker M.E., Katsu Y. Progesterone: an enigmatic ligand for the mineralocorticoid receptor. Biochem Pharmacol 2020;177:113976.
DOI: 10.1016/j.bcp.2020.113976
Ohlsson C., Langenskiöld M., Smidfelt K. et al. Low progesterone and low estradiol levels associate with abdominal aortic aneurysms in men. J Clin Endocrinol Metab 2022;107(4):e1413–25.
DOI: 10.1210/clinem/dgab867
Ghandehari S., Matusov Y., Pepkowitz S. et al. Progesterone in addition to standard of care vs standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled pilot trial. Chest 2021;160(1):74–84.
DOI: 10.1016/j.chest.2021.02.024
Gadkar-Sable S., Shah C., Rosario G. et al. Progesterone receptors: various forms and functions in reproductive tissues. Front Biosci 2005;10:2118–30.
DOI: 10.2741/1685.
Shackleton C., Malunowicz E. Apparent pregnene hydroxylation deficiency (APDH): seeking the parentage of an orphan metabolome. Steroids 2003;68(9):707–17.
DOI: 10.1016/s0039-128x(03)00115-6
Naville D., Keeney D.S., Jenkin G. et al. Regulation of expression of male-specific rat liver microsomal 3 beta-hydroxysteroid dehydrogenase. Mol Endocrinol 1991;5(8):1090–100.
DOI: 10.1016/s0039- 10.1210/mend-5-8-1090
Zumoff B., Miller L., Levin J. et al. Follicular-phase serum progesterone levels of nonsmoking women do not differ from the levels of nonsmoking men. Steroids 1990;55(12):557–9.
DOI: 10.1016/0039-128x(90)90052-d
Winkelmann B.R., März W., Boehm B.O. et al. Rationale and design of the LURIC study – a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2(Suppl 1):S1–73.
DOI: 10.1517/14622416.2.1.S1
Arnett-Mansfield R.L., deFazo A., Wain G.V. et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 2001;61(11):4576–82
Lieberman A., Curtis L. In defense of progesterone: a review of the literature. Altern Ther Health Med 2017; 23(6):24–32
Samadi A., Carlson C.G., Gueorguiev A., Cenedella R.J. Rapid, non-genomic actions of progesterone and estradiol on steady-state calcium and resting calcium influx in lens epithelial cells. Pflugers Arch 2002;444(6):700–9.
DOI: 10.1007/s00424-002-0889-7
Pedersen S.B., Kristensen K., Richelsen B. Anti-glucocorticoid effects of progesterone in vivo on rat adipose tissue metabolism. Steroids 2003;68(6):543–50.
DOI: 10.1016/s0039-128х(03)00084-9
Falkenstein E., Tillmann H.-C., Christ M. et al. Multiple actions of steroid hormones – a focus on rapid, nongenomic effects. Pharmacol Rev 2000;52(4):513–55
Rajaram R.D., Brisken C. Paracrine signaling by progesterone. Mol Cell Endocrinol 2012;357(1–2):80–90.
DOI: 10.1016/j.mce.2011.09.018
Sciarra A., Innocenzi M., Ravaziol M. et al.. Urologia 2011;78(2):126–31.
DOI: 10.5301/RU.2011.8337
Hermann M., Untergasser G., Rumpold H., Berger P. Aging of the male reproductive system. Exp Gerontol 2000;35(9–10): 1267–79.
DOI: 10.1016/s0531-5565(00)00159-5
Song L., Shen W., Zhang H. et al. Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia. Bosn J Basic Med Sci 2016;16(3):201–8.
DOI: 10.17305/bjbms.2016.1209
Chen R., Yu Y., Dong X. Progesterone receptor in the prostate: a potential suppressor for benign prostatic hyperplasia and prostate cancer. J Steroid Biochem Mol Biol 2017;166:91–6.
DOI: 10.1016/j.jsbmb.2016.04.008
Kaore S.N., Langade D.K., Yadav V.K. et al. Novel actions of progesterone: what we know today and what will be the scenario in the future? J Pharm Pharmacol 2012;64(8):1040–62.
DOI: 10.1111/j.2042-7158.2012.01464.х
Da Silva M.H.A., De Souza D.B. Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia. Res Rep Urol 2019;11:1–8.
DOI: 10.2147/RRU.S155609.
Fochi R.A., Santos F.C., Goes R.M., Taboga S.R. Progesterone as a morphological regulatory factor of the male and female gerbil prostate. Int J Exp Pathol 2013;94(6):373–86.
DOI: 10.1111/iep.12050
Yu Y., Yang O., Fazli L. et al. Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. Prostate 2015;75(10):1043–50.
DOI: 10.1002/pros.22988
Grindstad T., Andersen S., Al-Saad S. et al. High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS One 2015;10(2):e0116691.
DOI: 10.1371/journal.pone.0116691
Grindstad T., Richardsen E., Andersen S. et al. Progesterone receptors in prostate cancer: progesterone receptor B is the isoform associated with disease progression. Sci Rep 2018;8(1):11358.
DOI: 10.1038/s41598-018-29520-5
Spirina L.V., Kovaleva I.V., Usynin E.A. et al. Progesterone receptor expression in the benign prostatic hyperplasia and prostate cancer tissues, relation with transcription, growth factors, hormone reception and components of the AKT/mTOR signaling pathway. Asian Pac J Cancer Prev 2020;21(2):423–9.
DOI: 10.31557/APJCP.2020.21.2.423
Bera K.N., Yadav S.K., Prakash O. et al. Immunoexpression of estrogen receptor-β and progesterone receptor in prostate adenocarcinoma, does it inhibit neoplastic proliferation and invasion? Indian J Pathol Microbiol 2020; 63(Supplement): S30–S33.
DOI: 10.4103/IJPM.IJPM_467_18
Li W., Klein R.J. Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk. Prostate Cancer Prostatic Dis 2021;24(2):492–8.
DOI: 10.1038/s41391-020-00303-2
Yang M., Li J.C., Tao C. et al. PAQR6 upregulation is associated with AR signaling and unfavorite prognosis in prostate cancers. Biomolecules 2021;11(9):1383.
DOI: 10.3390/biom11091383
Tao C., Liu W., Yan X. et al. PAQR5 expression is suppressed by TGFβ1 and associated with a poor survival outcome in renal clear cell carcinoma. Front Oncol 2022;11:827344.
DOI: 10.3389/fonc.2021.827344
Check J.H. The role of progesterone and the progesterone receptor in cancer. Expert Rev Endocrinol Metab 2017;12(3):187–97.
DOI: 10.1080/17446651.2017.1314783
Pitchford A.G. Gestronol hexanoate (SH582) and benign prostatic hypertrophy. Proc R Soc Med 1972;65(2):128–9
Ibba A.L.. Osp Ital Chir 1968;19(4):427–42
Musierowicz A.. Wiad Lek 1974;27(22):1985–8
Щербаков А.П. Применение прогестерона при аденоме предстательной железы. Урология и нефрология 1978;1:72–6.
Nagel R., Hargenda B.. Hinyokika Kiyo 1970;16(9):423–8
Momose S., Hidaka M., Oota Y., Oomaru K.. Hinyokika Kiyo 1970;16(9):551–4
Tanaka H., Fukushige M., Shiraishi T.. Hinyokika Kiyo 1970;16(9):531–50
Meiraz D., Margolin Y., Lev-Ran A., Lazebnik J. Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study. Urology 1977;9(2):144–8.
DOI: 10.1016/0090-4295(77)90184-4
Schacter L., Rozencweig M., Canetta R. et al. Megestrol acetate: clinical experience. Cancer Treat Rev 1989;16(1):49–63.
DOI: 10.1016/0305-7372(89)90004-2
Карпушин В.Т., Сапожников В.В. Фонофорез гидроксипрогестерона капроната в лечении больных с аденомой предстательной железы, осложненной дизурией. Вопросы курортологии и физиотерапии. 1981;6:46–9
Григорьева В.Д., Сапожников В.В., Пономарев Ю.Т. и др. Применение ректального фонофореза гидроксипрогестерона капроната для коррекции эндокринных нарушений у пациентов с аденомой простаты. Вопросы курортологии и физиотерапии 1984;6:29–32
Onu P.E. Depot medroxyprogesterone in the management of benign prostatic hyperplasia. Eur Urol 1995;28(3):229–35.
DOI: 10.1159/000475056
Albouy M., Sanquer A., Maynard L., Eun H.M. Efficacies of osaterone and delmadinone in the treatment of benign prostatichyperplasia in dogs. Vet Rec 2008;163(6):179–83.
DOI: 10.1136/vr.163.6.179
Fujimoto K., Hirao Y., Ohashi Y. et al. The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study. Adv Urol 2013;2013:584678.
DOI: 10.1155/2013/584678
Li W., Li X., Zhang B. et al. Current progresses and trends in the development of progesterone receptor modulators. Curr Med Chem 2016;23(23):2507–54.
DOI: 10.2174/0929867323666160428105310
Bouchard P. Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology. Gynecol Endocrinol 2014;30(10):683–4.
DOI: 10.3109/09513590.2014.950647